ViiV Healthcare

135 articles about ViiV Healthcare

• 3D Communications Expands its Executive Communications and Value Communications Programs with Hiring of Former Industry Executive

  2/5/2019

  Cara Vivarelli-O'Neill brings two decades of pharmaceutical and healthcare industry experience

• 

  As Part of Global Restructuring, GlaxoSmithKline Pink-Slips 650 in the U.S.

  9/6/2018

  As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
• 

  Updated: Merck Scores FDA Approval for Two New HIV Treatments

  8/31/2018

  Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
• 

  J&J Reports Positive Phase III Data for its Two-Drug HIV Combo

  8/15/2018

  Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.

• ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

  7/24/2018

  Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks

• ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients

  7/24/2018

  GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads

• 

  GSK Trial Data Shows Strong Support for Two-Drug Regimen Option For Treating HIV Patients

  7/24/2018

  GlaxoSmithKline continues to make headway in the development of two-drug regimens to benefit HIV patients – even those who have high levels of the virus.

• ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 2018

  7/18/2018

  ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands.

• 

  GSK’s Duo-Combo HIV Treatment Gives Positive Trial Results

  6/14/2018

  ViiV Healthcare, established in November 2009 by GlaxoSmithKline, Pfizer and Shiongi, reported positive results from its Phase III GEMINI-1 and -2 clinical trials.
• 

  GlaxoSmithKline's ViiV Healthcare Wins First FDA OK for Two-Drug HIV Regimen

  11/22/2017

  HIV patients have a new maintenance drug in their arsenal of medication.

• ViiV Healthcare Announces Superior Efficacy Of Dolutegravir Versus Lopinavir/Ritonavir In Second-Line HIV Treatment In Resource-Limited Settings

  7/25/2017

• bioMONTR Labs Release: Company Announces Laboratory Service Agreements With ViiV Healthcare

  1/25/2017

• Primary Endpoint Met in ViiV Healthcare's Two Phase III Trials of Two-Drug HIV Treatment Regimen

  12/20/2016

• More Changes at GlaxoSmithKline as ViiV Healthcare CEO Steps Down, New Leader Named

  12/6/2016

• ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment

  8/16/2016

• ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV

  7/18/2016

• ViiV Healthcare Announces FDA Approval To Lower The Weight Limit For Dolutegravir In Children And Adolescents Living With HIV

  6/10/2016

• ViiV Healthcare And The International Association Of Providers Of AIDS Care (IAPAC) To Collaborate On Fast-Track Cities

  5/31/2016

• ViiV Healthcare, Medicines Patent Pool Extend Licence For Dolutegravir To All Lower Middle-Income Countries

  4/25/2016

• ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

  2/25/2016